Qubit pharmaceuticals secures 16.1 million euros in seed round to revolutionize drug discovery
The Quantum Insider - 10-Jun-2022Developing a software platform that uses quantum computers to accelerate the discovery of new drugs
Join the club for FREE to access the whole archive and other member benefits.
CEO of Qubit Pharmaceuticals
Robert Marino has a diverse work experience spanning multiple roles at industries, and is currently the CEO of Qubit Pharmaceuticals. Prior to that, they co-founded and served as CEO of Deeptech Founders. He worked at idfinnov as a Business Unit Director, where they were responsible for technology detection, seeding, and commercialization. Robert also held the role of Business Developer at idfinnov.
Overall, Robert Marino has a strong background in leadership, business development, and research, with a focus on innovation and technology commercialization.
Robert began his education at Lycée Saint Louis from 2003 to 2005. Robert then attended Chimie ParisTech - PSL from 2005 to 2008, where he obtained a Master of Science in Chemistry with a focus on Chemistry, Management, and Entrepreneurship. In 2007-2008, he also pursued a Master's degree in Applied Physics at Pierre and Marie Curie University. Continuing their educational journey, he pursued a PhD in Material Sciences from 2008 to 2011.
Visit website: https://www.qubit-pharmaceuticals.com/#RoberMarino
See also: Qubit Pharmaceuticals - Drug discovery company based on quantum technology
Details last updated 21-Nov-2023
Developing a software platform that uses quantum computers to accelerate the discovery of new drugs